Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-025779

CHIEF FINANCIAL OFFICER sold 6,250 shares at an average $28.56 ($178,485)

  • CHIEF FINANCIAL OFFICER acquired 6,250 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Hohl Benjamin · CHIEF FINANCIAL OFFICER

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2024-10-28 Exercise or conversion : show line 1 in the form 10b5-1 +6,250 $2.48 $15,500 6,250 D
2024-10-28 Sale : show line 2 in the form 10b5-1 −5,600 $28.49 $159,562 650 D
2024-10-28 Sale : show line 3 in the form 10b5-1 −650 $29.11 $18,922 0 D
Open-market sales · 6,250 sh · avg $28.56 · $178,485

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2024-10-28 Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (right to buy) −6,250 173,806 D
Loading xslF345X05/form4-10302024_101039.xml…